Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing ...

The approval removes one shareholder hurdle, but the transaction still depends on customary closing conditions and remaining ...

Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the ...

The purpose-built site is fully operational and produces materials to support developers working on cell therapies globally.

Bio-Techne, a Minneapolis-based provider of life sciences tools, reagents, and diagnostic products, has announced that its shareholders have approved the company's proposed acquisition by Merck KGaA, ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the Minneapolis-based group Bio-Techne, according to a news release posted ...

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the ...

Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...